Retour

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology

News Clinical Study

- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment -

GlobeNewswire Inc. • 30/04/2024 à 00:30:00
Rhythm Pharmaceuticals, Inc. Common Stock
Address: 222 BERKELEY STREET
Postal Code: 02116
City: BOSTON
State: MA
Phone Number: 857-264-4280
Website: http://www.rhythmtx.com
Status: Active
Company Info

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

List Date2017-10-05
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001649904
Composite figiBBG007DLZ601
Share Class figiBBG007DLZ629
Market Cap2,386,479,658 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees226
Share Class Shares Outstanding60970000
Weighted Shares Outstanding60972909
Round Lot100
Updated date2024-05-12
Stats
Last 5 days
15-05
14-05
13-05
10-05
9-05
Last
39.595
38.941
39.745
39.164
39.154
Variance
-1.94%
-2.02%
1.48%
0.02%
-0.81%
Open
40.38
39.745
39.165
39.155
39.475
Highest
41.724
40.981
40.843
39.505
39.734
Lowest
41.71
40.955
40.725
39.447
39.651
History
PeriodVarhighestlowest
1 week
-0.25%
39.734
39.447
1 month
-11.67%
44.575
38.82
3 month
-19.63%
49.882
38.82
6 month
-19.63%
49.882
38.82
1 year
-19.63%
49.882
38.82
3 year
-19.63%
49.882
38.82
5 year
-19.63%
49.882
38.82
10 year
-19.63%
49.882
38.82
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-02 2023-08-01 2023-11-08 UNPUB
Assets 345,678,000 309,943,000 354,199,000 UNPUB
Current Assets 317,838,000 283,878,000 329,201,000 UNPUB
Current Liabilities 46,029,000 46,103,000 50,144,000 UNPUB
Equity 219,763,000 182,285,000 197,474,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 219,763,000 182,285,000 197,474,000 UNPUB
Liabilities 125,915,000 127,658,000 156,725,000 UNPUB
Liabilities And Equity 345,678,000 309,943,000 354,199,000 UNPUB
Noncurrent Assets 27,840,000 26,065,000 24,998,000 UNPUB
Noncurrent Liabilities 79,886,000 81,555,000 106,581,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-02 2023-08-01 2023-11-08 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -18,102,000 6,136,000 -51,168,000 UNPUB
Net Cash Flow, Continuing -18,102,000 6,136,000 -51,168,000 UNPUB
Net Cash Flow From Financing Activities -133,000 -965,000 73,043,000 UNPUB
Net Cash Flow From Financing Activities, Continuing -133,000 -965,000 73,043,000 UNPUB
Net Cash Flow From Investing Activities 18,464,000 48,191,000 -94,960,000 UNPUB
Net Cash Flow From Investing Activities, Continuing 18,464,000 48,191,000 -94,960,000 UNPUB
Net Cash Flow From Operating Activities -36,433,000 -41,090,000 -29,251,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -36,433,000 -41,090,000 -29,251,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-02 2023-08-01 2023-11-08 UNPUB
Comprehensive Income/Loss -52,093,000 -46,711,000 -44,262,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -52,093,000 -46,711,000 -44,262,000 UNPUB
Other Comprehensive Income/Loss 86,000 -46,711,000 -44,262,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-02 2023-08-01 2023-11-08 UNPUB
Basic Earnings Per Share -1 -1 -1 UNPUB
Benefits Costs and Expenses 63,648,000 65,825,000 66,299,000 UNPUB
Cost Of Revenue 1,421,000 2,236,000 2,412,000 UNPUB
Costs And Expenses 64,000,000 65,825,000 66,457,000 UNPUB
Diluted Earnings Per Share -1 -1 -1 UNPUB
Gross Profit 10,048,000 16,985,000 20,092,000 UNPUB
Income/Loss From Continuing Operations After Tax -52,179,000 -46,703,000 -44,163,000 UNPUB
Income/Loss From Continuing Operations Before Tax -52,179,000 -46,604,000 -43,795,000 UNPUB
Income Tax Expense/Benefit 0 0 368,000 UNPUB
Interest Expense, Operating 3,061,000 3,303,000 3,149,000 UNPUB
Net Income/Loss -52,179,000 -46,703,000 -44,163,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -52,179,000 -46,703,000 -44,163,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -52,179,000 -46,703,000 -44,163,000 UNPUB
Operating Expenses 62,579,000 63,589,000 64,045,000 UNPUB
Operating Income/Loss -52,531,000 -46,604,000 -43,953,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 11,469,000 19,221,000 22,504,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-03 2022-08-03 2022-11-08 2023-03-01
Assets 284,824,000 277,675,000 389,614,000 382,481,000
Current Assets 253,449,000 249,332,000 361,874,000 354,236,000
Current Liabilities 47,274,000 44,570,000 33,098,000 39,809,000
Equity 235,769,000 195,628,000 281,195,000 264,262,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 235,769,000 195,628,000 281,195,000 264,262,000
Liabilities 49,055,000 82,047,000 108,419,000 118,219,000
Liabilities And Equity 284,824,000 277,675,000 389,614,000 382,481,000
Noncurrent Assets 31,375,000 28,343,000 27,740,000 28,245,000
Noncurrent Liabilities 0 0 75,321,000 78,410,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-03 2022-08-03 2022-11-08 2023-03-01
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 19,289,000 34,670,000 71,880,000 68,429,000
Net Cash Flow, Continuing 19,289,000 34,670,000 71,880,000 68,429,000
Net Cash Flow From Financing Activities 399,000 37,500,000 158,564,000 213,828,000
Net Cash Flow From Financing Activities, Continuing 399,000 37,500,000 158,564,000 213,828,000
Net Cash Flow From Investing Activities 72,522,000 35,979,000 -39,697,000 28,029,000
Net Cash Flow From Investing Activities, Continuing 72,522,000 35,979,000 -39,697,000 28,029,000
Net Cash Flow From Operating Activities -53,632,000 -38,809,000 -46,987,000 -173,428,000
Net Cash Flow From Operating Activities, Continuing -53,632,000 -38,809,000 -46,987,000 -173,428,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-03 2022-08-03 2022-11-08 2023-03-01
Comprehensive Income/Loss -52,764,000 -45,001,000 -40,294,000 -181,210,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -53,392,000 -45,278,000 -40,294,000 -181,210,000
Other Comprehensive Income/Loss 0 0 -40,294,000 -91,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-03 2022-08-03 2022-11-08 2023-03-01
Basic Earnings Per Share -1 -1 -1 -3
Benefits Costs and Expenses 54,262,000 54,067,000 45,145,000 204,757,000
Cost Of Revenue 230,000 378,000 497,000 2,133,000
Costs And Expenses 54,189,000 54,162,000 43,551,000 202,795,000
Diluted Earnings Per Share -1 -1 -1 -3
Gross Profit 1,268,000 8,688,000 3,787,000 21,505,000
Income/Loss From Continuing Operations After Tax -52,764,000 -45,001,000 -40,861,000 -181,119,000
Income/Loss From Continuing Operations Before Tax -52,764,000 -45,001,000 -40,861,000 -181,119,000
Income Tax Expense/Benefit 0 UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB 2,144,000 5,201,000
Net Income/Loss -52,764,000 -45,001,000 -40,861,000 -181,119,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -52,764,000 -45,001,000 -40,861,000 -181,119,000
Net Income/Loss Available To Common Stockholders, Basic -52,764,000 -45,001,000 -40,861,000 -181,119,000
Operating Expenses 53,959,000 53,784,000 43,054,000 200,662,000
Operating Income/Loss -52,691,000 -45,096,000 -39,267,000 -179,157,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 1,498,000 9,066,000 4,284,000 23,638,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-03 2021-08-03 2021-11-02 2022-03-01
Assets 422,209,000 388,390,000 355,823,000 329,523,000
Current Assets 412,134,000 378,454,000 335,636,000 308,387,000
Current Liabilities 16,850,000 17,459,000 23,467,000 43,427,000
Equity 380,947,000 351,689,000 322,263,000 284,151,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 380,947,000 351,689,000 322,263,000 284,151,000
Liabilities 41,262,000 36,701,000 33,560,000 45,372,000
Liabilities And Equity 422,209,000 388,390,000 355,823,000 329,523,000
Noncurrent Assets 10,075,000 9,936,000 20,187,000 21,136,000
Noncurrent Liabilities 0 0 10,093,000 1,945,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-03 2021-08-03 2021-11-02 2022-03-01
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -13,658,000 -17,932,000 23,033,000 -41,681,000
Net Cash Flow, Continuing -13,658,000 -17,932,000 23,033,000 -41,681,000
Net Cash Flow From Financing Activities 165,585,000 383,000 413,000 166,481,000
Net Cash Flow From Financing Activities, Continuing 165,585,000 383,000 413,000 166,481,000
Net Cash Flow From Investing Activities -145,712,000 13,525,000 62,780,000 -62,159,000
Net Cash Flow From Investing Activities, Continuing -145,712,000 13,525,000 62,780,000 -62,159,000
Net Cash Flow From Operating Activities -33,531,000 -31,840,000 -40,160,000 -146,003,000
Net Cash Flow From Operating Activities, Continuing -33,531,000 -31,840,000 -40,160,000 -146,003,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-03 2021-08-03 2021-11-02 2022-03-01
Comprehensive Income/Loss 43,750,000 -35,389,000 -35,107,000 -69,613,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent 43,643,000 -35,310,000 -35,107,000 -69,613,000
Other Comprehensive Income/Loss 0 0 -35,107,000 -1,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-03 2021-08-03 2021-11-02 2022-03-01
Basic Earnings Per Share 1 -1 UNPUB -1
Benefits Costs and Expenses -65,721,000 40,685,000 45,268,000 72,766,000
Cost Of Revenue 4,000 137,000 222,000 599,000
Costs And Expenses 34,433,000 40,706,000 45,268,000 173,213,000
Diluted Earnings Per Share 1 -1 UNPUB -1
Gross Profit 31,000 137,000 806,000 2,555,000
Income/Loss From Continuing Operations After Tax 43,750,000 -35,389,000 -44,102,000 -69,612,000
Income/Loss From Continuing Operations Before Tax 65,756,000 -40,411,000 -44,240,000 -69,612,000
Income Tax Expense/Benefit 22,006,000 -5,022,000 -8,995,000 UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss 43,750,000 -35,389,000 -35,107,000 -69,612,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent 43,750,000 -35,389,000 -35,107,000 -69,612,000
Net Income/Loss Available To Common Stockholders, Basic 43,750,000 -35,389,000 -35,107,000 -69,612,000
Operating Expenses 34,429,000 40,569,000 45,046,000 172,614,000
Operating Income/Loss -34,398,000 -40,432,000 -44,240,000 -170,059,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 35,000 274,000 1,028,000 3,154,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-04 2020-08-03 2020-11-02 2021-03-01
Assets 273,756,000 243,485,000 215,477,000 187,073,000
Current Assets 267,860,000 237,819,000 209,914,000 181,668,000
Current Liabilities 17,696,000 14,904,000 15,848,000 17,994,000
Equity 253,101,000 225,753,000 196,937,000 166,528,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 253,101,000 225,753,000 196,937,000 166,528,000
Liabilities 20,655,000 17,732,000 18,540,000 20,545,000
Liabilities And Equity 273,756,000 243,485,000 215,477,000 187,073,000
Noncurrent Assets 5,896,000 5,666,000 5,563,000 5,405,000
Noncurrent Liabilities 0 0 2,692,000 2,551,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-04 2020-08-03 2020-11-02 2021-03-01
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -6,518,000 3,315,000 8,579,000 38,560,000
Net Cash Flow, Continuing -6,518,000 3,315,000 8,579,000 38,560,000
Net Cash Flow From Financing Activities 707,000 183,000 699,000 2,009,000
Net Cash Flow From Financing Activities, Continuing 707,000 183,000 699,000 2,009,000
Net Cash Flow From Investing Activities 28,873,000 32,861,000 34,910,000 158,531,000
Net Cash Flow From Investing Activities, Continuing 28,873,000 32,861,000 34,910,000 158,531,000
Net Cash Flow From Operating Activities -36,098,000 -29,729,000 -27,030,000 -121,980,000
Net Cash Flow From Operating Activities, Continuing -36,098,000 -29,729,000 -27,030,000 -121,980,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-04 2020-08-03 2020-11-02 2021-03-01
Comprehensive Income/Loss -34,164,000 -31,117,000 -34,210,000 -133,947,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -34,101,000 -30,550,000 -34,210,000 -133,947,000
Other Comprehensive Income/Loss 0 0 -392,000 49,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-04 2020-08-03 2020-11-02 2021-03-01
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -34,164,000 -31,117,000 -33,818,000 -133,996,000
Income/Loss From Continuing Operations Before Tax -34,164,000 -31,117,000 -33,818,000 -133,996,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -34,164,000 -31,117,000 -33,818,000 -133,996,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -34,164,000 -31,117,000 -33,818,000 -133,996,000
Net Income/Loss Available To Common Stockholders, Basic -34,164,000 -31,117,000 -33,818,000 -133,996,000
Operating Expenses 35,300,000 31,918,000 34,284,000 136,575,000
Operating Income/Loss -35,300,000 -31,918,000 -34,284,000 -136,575,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-03 2019-07-29 2019-11-01 2020-03-02
Assets 236,502,000 210,888,000 177,533,000 308,523,000
Current Assets 230,169,000 203,501,000 170,877,000 302,404,000
Current Liabilities 12,567,000 26,090,000 25,207,000 24,417,000
Equity 220,489,000 181,467,000 149,115,000 281,020,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 220,489,000 181,467,000 149,115,000 281,020,000
Liabilities 16,013,000 29,421,000 28,418,000 27,503,000
Liabilities And Equity 236,502,000 210,888,000 177,533,000 308,523,000
Noncurrent Assets 6,333,000 7,387,000 6,656,000 6,119,000
Noncurrent Liabilities 0 0 3,211,000 3,086,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-03 2019-07-29 2019-11-01 2020-03-02
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -7,521,000 21,097,000 8,563,000 12,754,000
Net Cash Flow, Continuing -7,521,000 21,097,000 8,563,000 12,754,000
Net Cash Flow From Financing Activities 316,000 498,000 697,000 163,474,000
Net Cash Flow From Financing Activities, Continuing 316,000 498,000 697,000 163,474,000
Net Cash Flow From Investing Activities 23,541,000 46,145,000 41,471,000 -27,970,000
Net Cash Flow From Investing Activities, Continuing 23,541,000 46,145,000 41,471,000 -27,970,000
Net Cash Flow From Operating Activities -31,378,000 -25,546,000 -33,605,000 -122,750,000
Net Cash Flow From Operating Activities, Continuing -31,378,000 -25,546,000 -33,605,000 -122,750,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-03 2019-07-29 2019-11-01 2020-03-02
Comprehensive Income/Loss -28,974,000 -42,796,000 -36,003,000 -140,729,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -28,974,000 -42,796,000 -36,003,000 -140,729,000
Other Comprehensive Income/Loss 0 0 0 -140,585,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-03 2019-07-29 2019-11-01 2020-03-02
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -28,974,000 -42,796,000 -36,003,000 -140,729,000
Income/Loss From Continuing Operations Before Tax -28,974,000 -42,796,000 -36,003,000 -140,729,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -28,974,000 -42,796,000 -36,003,000 -140,729,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -28,974,000 -42,796,000 -36,003,000 -140,729,000
Net Income/Loss Available To Common Stockholders, Basic -28,974,000 -42,796,000 -36,003,000 -140,729,000
Operating Expenses 30,520,000 44,149,000 37,107,000 146,000,000
Operating Income/Loss -30,520,000 -44,149,000 -37,107,000 -146,000,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2018-05-14 2018-08-08 2018-11-09 2019-03-08
Assets 139,443,000 291,749,000 277,728,000 260,210,000
Current Assets 138,414,000 290,771,000 276,538,000 258,689,000
Current Liabilities 5,579,000 7,247,000 7,803,000 13,582,000
Equity 133,658,000 284,317,000 269,637,000 246,256,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 133,658,000 284,317,000 269,637,000 246,256,000
Liabilities 5,785,000 7,432,000 8,091,000 13,954,000
Liabilities And Equity 139,443,000 291,749,000 277,728,000 260,210,000
Noncurrent Assets 1,029,000 978,000 1,190,000 1,521,000
Noncurrent Liabilities 206,000 185,000 288,000 372,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2018-05-14 2018-08-08 2018-11-09 2019-03-08
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 176,273,000 -152,236,000 15,482,000
Net Cash Flow, Continuing 0 176,273,000 -152,236,000 15,482,000
Net Cash Flow From Financing Activities -8,956,000 172,316,000 1,173,000 164,686,000
Net Cash Flow From Financing Activities, Continuing -8,956,000 172,316,000 1,173,000 164,686,000
Net Cash Flow From Investing Activities 20,607,000 16,437,000 -136,467,000 -87,148,000
Net Cash Flow From Investing Activities, Continuing 20,607,000 16,437,000 -136,467,000 -87,148,000
Net Cash Flow From Operating Activities -11,651,000 -12,480,000 -16,942,000 -62,056,000
Net Cash Flow From Operating Activities, Continuing -11,651,000 -12,480,000 -16,942,000 -62,056,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2018-05-14 2018-08-08 2018-11-09 2019-03-08
Comprehensive Income/Loss -16,459,000 -14,412,000 -17,686,000 -74,064,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -16,459,000 -14,412,000 -17,686,000 -74,064,000
Other Comprehensive Income/Loss 0 0 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2018-05-14 2018-08-08 2018-11-09 2019-03-08
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -16,459,000 -14,412,000 -17,686,000 -74,064,000
Income/Loss From Continuing Operations Before Tax -16,459,000 -14,412,000 -17,686,000 -74,064,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -16,459,000 -14,412,000 -17,686,000 -74,064,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -16,459,000 -14,412,000 -17,686,000 -74,064,000
Net Income/Loss Available To Common Stockholders, Basic -16,459,000 -14,412,000 -17,686,000 -74,064,000
Operating Expenses 17,001,000 15,021,000 19,244,000 78,417,000
Operating Income/Loss -17,001,000 -15,021,000 -19,244,000 -78,417,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2018-03-12
Assets UNPUB UNPUB UNPUB 151,736,000
Current Assets UNPUB UNPUB UNPUB 150,671,000
Current Liabilities UNPUB UNPUB UNPUB 6,720,000
Equity UNPUB UNPUB UNPUB 144,788,000
Equity Attributable To Noncontrolling Interest UNPUB UNPUB UNPUB 0
Equity Attributable To Parent UNPUB UNPUB UNPUB 144,788,000
Liabilities UNPUB UNPUB UNPUB 6,948,000
Liabilities And Equity UNPUB UNPUB UNPUB 151,736,000
Noncurrent Assets UNPUB UNPUB UNPUB 1,065,000
Noncurrent Liabilities UNPUB UNPUB UNPUB 228,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2018-03-12
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB UNPUB UNPUB 27,696,000
Net Cash Flow, Continuing UNPUB UNPUB UNPUB 27,696,000
Net Cash Flow From Financing Activities UNPUB UNPUB UNPUB 167,200,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB UNPUB 167,200,000
Net Cash Flow From Investing Activities UNPUB UNPUB UNPUB -110,044,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB UNPUB -110,044,000
Net Cash Flow From Operating Activities UNPUB UNPUB UNPUB -29,460,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB UNPUB -29,460,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2018-03-12
Comprehensive Income/Loss UNPUB UNPUB UNPUB -33,709,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB UNPUB 0
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB -33,709,000
Other Comprehensive Income/Loss UNPUB UNPUB UNPUB 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2018-03-12
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB UNPUB UNPUB -33,709,000
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB UNPUB -33,709,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB UNPUB UNPUB -33,709,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB UNPUB 3,873,000
Net Income/Loss Attributable To Parent UNPUB UNPUB UNPUB -37,582,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB UNPUB -37,582,000
Operating Expenses UNPUB UNPUB UNPUB 32,412,000
Operating Income/Loss UNPUB UNPUB UNPUB -32,412,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB UNPUB 0
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB UNPUB 0
Revenues UNPUB UNPUB UNPUB 0
Calendar
16 May 2024 (Time UTC) Actual Previous Consensus
★
15:50
United States
★★
11:30
United States
★
11:30
United States
5.275
★
11:30
United States
5.270
★
11:30
United States
★
11:30
United States
★★
10:30
United States
★
10:30
United States
MAY 10
70000000000.000
79000000000.000
76000000000.000
★
10:30
United States
MAY 10
★★
10:00
United States
★
09:15
United States
APR
-0.300
0.200
0.100
★★
09:15
United States
APR
-0.380
0.090
★
09:15
United States
APR
78.400
78.500
78.400
★
09:15
United States
APR
★★
08:30
United States
APR
0.500
0.100
0.400
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:RYTM240419P00040000 OPASPS Put American 100 40 EMLD 2024-04-19
O:RYTM240419P00035000 OPASPS Put American 100 35 EMLD 2024-04-19
O:RYTM240419P00030000 OPASPS Put American 100 30 EMLD 2024-04-19
O:RYTM240419P00025000 OPASPS Put American 100 25 EMLD 2024-04-19
O:RYTM240419P00022500 OPASPS Put American 100 22.5 EMLD 2024-04-19
O:RYTM240419P00020000 OPASPS Put American 100 20 EMLD 2024-04-19
O:RYTM240419P00017500 OPASPS Put American 100 17.5 EMLD 2024-04-19
O:RYTM240419P00015000 OPASPS Put American 100 15 EMLD 2024-04-19
O:RYTM240419C00040000 OCASPS Call American 100 40 EMLD 2024-04-19
O:RYTM240419C00035000 OCASPS Call American 100 35 EMLD 2024-04-19
O:RYTM240419C00030000 OCASPS Call American 100 30 EMLD 2024-04-19
O:RYTM240419C00025000 OCASPS Call American 100 25 EMLD 2024-04-19
O:RYTM240419C00022500 OCASPS Call American 100 22.5 EMLD 2024-04-19
O:RYTM240419C00020000 OCASPS Call American 100 20 EMLD 2024-04-19
O:RYTM240419C00017500 OCASPS Call American 100 17.5 EMLD 2024-04-19
O:RYTM240419C00015000 OCASPS Call American 100 15 EMLD 2024-04-19
O:RYTM240419P00070000 OPASPS Put American 100 70 BATO 2024-04-19
O:RYTM240419P00065000 OPASPS Put American 100 65 BATO 2024-04-19
O:RYTM240419P00060000 OPASPS Put American 100 60 BATO 2024-04-19
O:RYTM240419P00055000 OPASPS Put American 100 55 BATO 2024-04-19
O:RYTM240419P00050000 OPASPS Put American 100 50 BATO 2024-04-19
O:RYTM240419P00045000 OPASPS Put American 100 45 BATO 2024-04-19
O:RYTM240419C00070000 OCASPS Call American 100 70 BATO 2024-04-19
O:RYTM240419C00065000 OCASPS Call American 100 65 BATO 2024-04-19
O:RYTM240419C00060000 OCASPS Call American 100 60 BATO 2024-04-19
O:RYTM240419C00055000 OCASPS Call American 100 55 BATO 2024-04-19
O:RYTM240419C00050000 OCASPS Call American 100 50 BATO 2024-04-19
O:RYTM240419C00045000 OCASPS Call American 100 45 BATO 2024-04-19
O:RYTM240419P00012500 OPASPS Put American 100 12.5 EMLD 2024-04-19
O:RYTM240419C00012500 OCASPS Call American 100 12.5 EMLD 2024-04-19
O:RYTM240315P00070000 OPASPS Put American 100 70 BATO 2024-03-15
O:RYTM240315P00065000 OPASPS Put American 100 65 BATO 2024-03-15
O:RYTM240315C00070000 OCASPS Call American 100 70 BATO 2024-03-15
O:RYTM240315C00065000 OCASPS Call American 100 65 BATO 2024-03-15
O:RYTM240315P00060000 OPASPS Put American 100 60 BATO 2024-03-15
O:RYTM240315P00055000 OPASPS Put American 100 55 BATO 2024-03-15
O:RYTM240315P00050000 OPASPS Put American 100 50 BATO 2024-03-15
O:RYTM240315P00045000 OPASPS Put American 100 45 BATO 2024-03-15
O:RYTM240315P00040000 OPASPS Put American 100 40 BATO 2024-03-15
O:RYTM240315P00035000 OPASPS Put American 100 35 BATO 2024-03-15
O:RYTM240315P00030000 OPASPS Put American 100 30 BATO 2024-03-15
O:RYTM240315P00025000 OPASPS Put American 100 25 BATO 2024-03-15
O:RYTM240315P00022500 OPASPS Put American 100 22.5 BATO 2024-03-15
O:RYTM240315P00020000 OPASPS Put American 100 20 BATO 2024-03-15
O:RYTM240315C00060000 OCASPS Call American 100 60 BATO 2024-03-15
O:RYTM240315C00055000 OCASPS Call American 100 55 BATO 2024-03-15
O:RYTM240315C00050000 OCASPS Call American 100 50 BATO 2024-03-15
O:RYTM240315C00045000 OCASPS Call American 100 45 BATO 2024-03-15
O:RYTM240315C00040000 OCASPS Call American 100 40 BATO 2024-03-15
O:RYTM240315C00035000 OCASPS Call American 100 35 BATO 2024-03-15
O:RYTM240315C00030000 OCASPS Call American 100 30 BATO 2024-03-15
O:RYTM240315C00025000 OCASPS Call American 100 25 BATO 2024-03-15
O:RYTM240315C00022500 OCASPS Call American 100 22.5 BATO 2024-03-15
O:RYTM240315C00020000 OCASPS Call American 100 20 BATO 2024-03-15
O:RYTM240216P00065000 OPASPS Put American 100 65 EMLD 2024-02-16
O:RYTM240216P00060000 OPASPS Put American 100 60 EMLD 2024-02-16
O:RYTM240216P00055000 OPASPS Put American 100 55 EMLD 2024-02-16
O:RYTM240216P00050000 OPASPS Put American 100 50 EMLD 2024-02-16
O:RYTM240216P00045000 OPASPS Put American 100 45 EMLD 2024-02-16
O:RYTM240216P00040000 OPASPS Put American 100 40 EMLD 2024-02-16
O:RYTM240216P00035000 OPASPS Put American 100 35 EMLD 2024-02-16
O:RYTM240216P00030000 OPASPS Put American 100 30 EMLD 2024-02-16
O:RYTM240216P00025000 OPASPS Put American 100 25 EMLD 2024-02-16
O:RYTM240216P00022500 OPASPS Put American 100 22.5 EMLD 2024-02-16
O:RYTM240216P00020000 OPASPS Put American 100 20 EMLD 2024-02-16
O:RYTM240216C00065000 OCASPS Call American 100 65 EMLD 2024-02-16
O:RYTM240216C00060000 OCASPS Call American 100 60 EMLD 2024-02-16
O:RYTM240216C00055000 OCASPS Call American 100 55 EMLD 2024-02-16
O:RYTM240216C00050000 OCASPS Call American 100 50 EMLD 2024-02-16
O:RYTM240216C00045000 OCASPS Call American 100 45 EMLD 2024-02-16
O:RYTM240216C00040000 OCASPS Call American 100 40 EMLD 2024-02-16
O:RYTM240216C00035000 OCASPS Call American 100 35 EMLD 2024-02-16
O:RYTM240216C00030000 OCASPS Call American 100 30 EMLD 2024-02-16
O:RYTM240216C00025000 OCASPS Call American 100 25 EMLD 2024-02-16
O:RYTM240216C00022500 OCASPS Call American 100 22.5 EMLD 2024-02-16
O:RYTM240216C00020000 OCASPS Call American 100 20 EMLD 2024-02-16
O:RYTM240216P00070000 OPASPS Put American 100 70 EMLD 2024-02-16
O:RYTM240216C00070000 OCASPS Call American 100 70 EMLD 2024-02-16
O:RYTM240119P00050000 OPASPS Put American 100 50 EMLD 2024-01-19
O:RYTM240119C00050000 OCASPS Call American 100 50 EMLD 2024-01-19
O:RYTM240119P00045000 OPASPS Put American 100 45 EMLD 2024-01-19
O:RYTM240119P00040000 OPASPS Put American 100 40 EMLD 2024-01-19
O:RYTM240119P00035000 OPASPS Put American 100 35 EMLD 2024-01-19
O:RYTM240119P00030000 OPASPS Put American 100 30 EMLD 2024-01-19
O:RYTM240119P00025000 OPASPS Put American 100 25 EMLD 2024-01-19
O:RYTM240119P00022500 OPASPS Put American 100 22.5 EMLD 2024-01-19
O:RYTM240119P00020000 OPASPS Put American 100 20 EMLD 2024-01-19
O:RYTM240119P00017500 OPASPS Put American 100 17.5 EMLD 2024-01-19
O:RYTM240119P00015000 OPASPS Put American 100 15 EMLD 2024-01-19
O:RYTM240119P00012500 OPASPS Put American 100 12.5 EMLD 2024-01-19
O:RYTM240119P00010000 OPASPS Put American 100 10 EMLD 2024-01-19
O:RYTM240119P00007500 OPASPS Put American 100 7.5 EMLD 2024-01-19
O:RYTM240119P00005000 OPASPS Put American 100 5 EMLD 2024-01-19
O:RYTM240119P00002500 OPASPS Put American 100 2.5 EMLD 2024-01-19
O:RYTM240119C00045000 OCASPS Call American 100 45 EMLD 2024-01-19
O:RYTM240119C00040000 OCASPS Call American 100 40 EMLD 2024-01-19
O:RYTM240119C00035000 OCASPS Call American 100 35 EMLD 2024-01-19
O:RYTM240119C00030000 OCASPS Call American 100 30 EMLD 2024-01-19
O:RYTM240119C00025000 OCASPS Call American 100 25 EMLD 2024-01-19
O:RYTM240119C00022500 OCASPS Call American 100 22.5 EMLD 2024-01-19
O:RYTM240119C00020000 OCASPS Call American 100 20 EMLD 2024-01-19
O:RYTM240119C00017500 OCASPS Call American 100 17.5 EMLD 2024-01-19
O:RYTM240119C00015000 OCASPS Call American 100 15 EMLD 2024-01-19
O:RYTM240119C00012500 OCASPS Call American 100 12.5 EMLD 2024-01-19
O:RYTM240119C00010000 OCASPS Call American 100 10 EMLD 2024-01-19
O:RYTM240119C00007500 OCASPS Call American 100 7.5 EMLD 2024-01-19
O:RYTM240119C00005000 OCASPS Call American 100 5 EMLD 2024-01-19
O:RYTM240119C00002500 OCASPS Call American 100 2.5 EMLD 2024-01-19
O:RYTM231215P00045000 OPASPS Put American 100 45 EMLD 2023-12-15
O:RYTM231215P00040000 OPASPS Put American 100 40 EMLD 2023-12-15
O:RYTM231215P00035000 OPASPS Put American 100 35 EMLD 2023-12-15
O:RYTM231215P00030000 OPASPS Put American 100 30 EMLD 2023-12-15
O:RYTM231215P00025000 OPASPS Put American 100 25 EMLD 2023-12-15
O:RYTM231215P00022500 OPASPS Put American 100 22.5 EMLD 2023-12-15
O:RYTM231215P00020000 OPASPS Put American 100 20 EMLD 2023-12-15
O:RYTM231215P00017500 OPASPS Put American 100 17.5 EMLD 2023-12-15
O:RYTM231215P00015000 OPASPS Put American 100 15 EMLD 2023-12-15
O:RYTM231215P00012500 OPASPS Put American 100 12.5 EMLD 2023-12-15
O:RYTM231215P00010000 OPASPS Put American 100 10 EMLD 2023-12-15
O:RYTM231215P00007500 OPASPS Put American 100 7.5 EMLD 2023-12-15
O:RYTM231215P00005000 OPASPS Put American 100 5 EMLD 2023-12-15
O:RYTM231215P00002500 OPASPS Put American 100 2.5 EMLD 2023-12-15
O:RYTM231215C00045000 OCASPS Call American 100 45 EMLD 2023-12-15
O:RYTM231215C00040000 OCASPS Call American 100 40 EMLD 2023-12-15
O:RYTM231215C00035000 OCASPS Call American 100 35 EMLD 2023-12-15
O:RYTM231215C00030000 OCASPS Call American 100 30 EMLD 2023-12-15
O:RYTM231215C00025000 OCASPS Call American 100 25 EMLD 2023-12-15
O:RYTM231215C00022500 OCASPS Call American 100 22.5 EMLD 2023-12-15
O:RYTM231215C00020000 OCASPS Call American 100 20 EMLD 2023-12-15
O:RYTM231215C00017500 OCASPS Call American 100 17.5 EMLD 2023-12-15
O:RYTM231215C00015000 OCASPS Call American 100 15 EMLD 2023-12-15
O:RYTM231215C00012500 OCASPS Call American 100 12.5 EMLD 2023-12-15
O:RYTM231215C00010000 OCASPS Call American 100 10 EMLD 2023-12-15
O:RYTM231215C00007500 OCASPS Call American 100 7.5 EMLD 2023-12-15
O:RYTM231215C00005000 OCASPS Call American 100 5 EMLD 2023-12-15
O:RYTM231215C00002500 OCASPS Call American 100 2.5 EMLD 2023-12-15
O:RYTM231117P00035000 OPASPS Put American 100 35 EMLD 2023-11-17
O:RYTM231117P00030000 OPASPS Put American 100 30 EMLD 2023-11-17
O:RYTM231117P00025000 OPASPS Put American 100 25 EMLD 2023-11-17
O:RYTM231117P00022500 OPASPS Put American 100 22.5 EMLD 2023-11-17
O:RYTM231117P00020000 OPASPS Put American 100 20 EMLD 2023-11-17
O:RYTM231117P00017500 OPASPS Put American 100 17.5 EMLD 2023-11-17
O:RYTM231117P00015000 OPASPS Put American 100 15 EMLD 2023-11-17
O:RYTM231117P00012500 OPASPS Put American 100 12.5 EMLD 2023-11-17
O:RYTM231117C00035000 OCASPS Call American 100 35 EMLD 2023-11-17
O:RYTM231117C00030000 OCASPS Call American 100 30 EMLD 2023-11-17
O:RYTM231117C00025000 OCASPS Call American 100 25 EMLD 2023-11-17
O:RYTM231117C00022500 OCASPS Call American 100 22.5 EMLD 2023-11-17
O:RYTM231117C00020000 OCASPS Call American 100 20 EMLD 2023-11-17
O:RYTM231117C00017500 OCASPS Call American 100 17.5 EMLD 2023-11-17
O:RYTM231117C00015000 OCASPS Call American 100 15 EMLD 2023-11-17
O:RYTM231117C00012500 OCASPS Call American 100 12.5 EMLD 2023-11-17
O:RYTM231020P00040000 OPASPS Put American 100 40 EMLD 2023-10-20
O:RYTM231020P00035000 OPASPS Put American 100 35 EMLD 2023-10-20
O:RYTM231020P00030000 OPASPS Put American 100 30 EMLD 2023-10-20
O:RYTM231020P00025000 OPASPS Put American 100 25 EMLD 2023-10-20
O:RYTM231020P00022500 OPASPS Put American 100 22.5 EMLD 2023-10-20
O:RYTM231020P00020000 OPASPS Put American 100 20 EMLD 2023-10-20
O:RYTM231020P00017500 OPASPS Put American 100 17.5 EMLD 2023-10-20
O:RYTM231020P00015000 OPASPS Put American 100 15 EMLD 2023-10-20
O:RYTM231020P00012500 OPASPS Put American 100 12.5 EMLD 2023-10-20
O:RYTM231020P00010000 OPASPS Put American 100 10 EMLD 2023-10-20
O:RYTM231020P00007500 OPASPS Put American 100 7.5 EMLD 2023-10-20
O:RYTM231020P00005000 OPASPS Put American 100 5 EMLD 2023-10-20
O:RYTM231020P00002500 OPASPS Put American 100 2.5 EMLD 2023-10-20
O:RYTM231020C00040000 OCASPS Call American 100 40 EMLD 2023-10-20
O:RYTM231020C00035000 OCASPS Call American 100 35 EMLD 2023-10-20
O:RYTM231020C00030000 OCASPS Call American 100 30 EMLD 2023-10-20
O:RYTM231020C00025000 OCASPS Call American 100 25 EMLD 2023-10-20
O:RYTM231020C00022500 OCASPS Call American 100 22.5 EMLD 2023-10-20
O:RYTM231020C00020000 OCASPS Call American 100 20 EMLD 2023-10-20
O:RYTM231020C00017500 OCASPS Call American 100 17.5 EMLD 2023-10-20
O:RYTM231020C00015000 OCASPS Call American 100 15 EMLD 2023-10-20
O:RYTM231020C00012500 OCASPS Call American 100 12.5 EMLD 2023-10-20
O:RYTM231020C00010000 OCASPS Call American 100 10 EMLD 2023-10-20
O:RYTM231020C00007500 OCASPS Call American 100 7.5 EMLD 2023-10-20
O:RYTM231020C00005000 OCASPS Call American 100 5 EMLD 2023-10-20
O:RYTM231020C00002500 OCASPS Call American 100 2.5 EMLD 2023-10-20
O:RYTM230915P00035000 OPASPS Put American 100 35 EMLD 2023-09-15
O:RYTM230915P00030000 OPASPS Put American 100 30 EMLD 2023-09-15
O:RYTM230915P00025000 OPASPS Put American 100 25 EMLD 2023-09-15
O:RYTM230915P00022500 OPASPS Put American 100 22.5 EMLD 2023-09-15
O:RYTM230915P00020000 OPASPS Put American 100 20 EMLD 2023-09-15
O:RYTM230915P00017500 OPASPS Put American 100 17.5 EMLD 2023-09-15
O:RYTM230915P00015000 OPASPS Put American 100 15 EMLD 2023-09-15
O:RYTM230915P00012500 OPASPS Put American 100 12.5 EMLD 2023-09-15
O:RYTM230915P00010000 OPASPS Put American 100 10 EMLD 2023-09-15
O:RYTM230915P00007500 OPASPS Put American 100 7.5 EMLD 2023-09-15
O:RYTM230915P00005000 OPASPS Put American 100 5 EMLD 2023-09-15
O:RYTM230915P00002500 OPASPS Put American 100 2.5 EMLD 2023-09-15
O:RYTM230915C00035000 OCASPS Call American 100 35 EMLD 2023-09-15
O:RYTM230915C00030000 OCASPS Call American 100 30 EMLD 2023-09-15
O:RYTM230915C00025000 OCASPS Call American 100 25 EMLD 2023-09-15
O:RYTM230915C00022500 OCASPS Call American 100 22.5 EMLD 2023-09-15
O:RYTM230915C00020000 OCASPS Call American 100 20 EMLD 2023-09-15
O:RYTM230915C00017500 OCASPS Call American 100 17.5 EMLD 2023-09-15
O:RYTM230915C00015000 OCASPS Call American 100 15 EMLD 2023-09-15
O:RYTM230915C00012500 OCASPS Call American 100 12.5 EMLD 2023-09-15
O:RYTM230915C00010000 OCASPS Call American 100 10 EMLD 2023-09-15
O:RYTM230915C00007500 OCASPS Call American 100 7.5 EMLD 2023-09-15
O:RYTM230915C00005000 OCASPS Call American 100 5 EMLD 2023-09-15
O:RYTM230915C00002500 OCASPS Call American 100 2.5 EMLD 2023-09-15
O:RYTM230818P00035000 OPASPS Put American 100 35 EMLD 2023-08-18
O:RYTM230818P00030000 OPASPS Put American 100 30 EMLD 2023-08-18
O:RYTM230818P00025000 OPASPS Put American 100 25 EMLD 2023-08-18
O:RYTM230818P00022500 OPASPS Put American 100 22.5 EMLD 2023-08-18
O:RYTM230818P00020000 OPASPS Put American 100 20 EMLD 2023-08-18
O:RYTM230818P00017500 OPASPS Put American 100 17.5 EMLD 2023-08-18
O:RYTM230818P00015000 OPASPS Put American 100 15 EMLD 2023-08-18
O:RYTM230818P00012500 OPASPS Put American 100 12.5 EMLD 2023-08-18
O:RYTM230818P00010000 OPASPS Put American 100 10 EMLD 2023-08-18
O:RYTM230818P00007500 OPASPS Put American 100 7.5 EMLD 2023-08-18
O:RYTM230818P00005000 OPASPS Put American 100 5 EMLD 2023-08-18
O:RYTM230818P00002500 OPASPS Put American 100 2.5 EMLD 2023-08-18
O:RYTM230818C00035000 OCASPS Call American 100 35 EMLD 2023-08-18
O:RYTM230818C00030000 OCASPS Call American 100 30 EMLD 2023-08-18
O:RYTM230818C00025000 OCASPS Call American 100 25 EMLD 2023-08-18
O:RYTM230818C00022500 OCASPS Call American 100 22.5 EMLD 2023-08-18
O:RYTM230818C00020000 OCASPS Call American 100 20 EMLD 2023-08-18
O:RYTM230818C00017500 OCASPS Call American 100 17.5 EMLD 2023-08-18
O:RYTM230818C00015000 OCASPS Call American 100 15 EMLD 2023-08-18
O:RYTM230818C00012500 OCASPS Call American 100 12.5 EMLD 2023-08-18
O:RYTM230818C00010000 OCASPS Call American 100 10 EMLD 2023-08-18
O:RYTM230818C00007500 OCASPS Call American 100 7.5 EMLD 2023-08-18
O:RYTM230818C00005000 OCASPS Call American 100 5 EMLD 2023-08-18
O:RYTM230818C00002500 OCASPS Call American 100 2.5 EMLD 2023-08-18
News Stream
News Clinical Study
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment -
GlobeNewswire Inc. • 2w ago
News Conference Calls/ Webcasts
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, May 7, 2024 to report its first quarter 2024 financial results and provide a corporate update.
GlobeNewswire Inc. • 3w ago
Stocks Changes in company's own shares
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on April 11, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 31,220 shares of its common stock to eight new employees, consisting of inducement stock options to purchase an aggregate of 16,480 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 14,740 shares of its common stock.
GlobeNewswire Inc. • 4w ago
Analyst Analyst Ratings
5 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
Analysts' ratings for Rhythm Pharmaceuticals (NASDAQ:RYTM) over the last quarter vary from bullish to bearish, as provided by 5 analysts. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 3 0 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $50.8, a high estimate of $52.00, and a low estimate of $50.00. This upward trend is evident, with the current average reflecting a 20.95% increase from the previous average price target of $42.00. Understanding Analyst Ratings: A Comprehensive Breakdown A clear picture of Rhythm Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Joseph Stringer Needham Maintains Buy $50.00 - Joseph Stringer Needham Maintains Buy $50.00 - Corinne Jenkins Goldman Sachs Raises Buy $52.00 $42.00 Joseph Stringer Needham Maintains Buy $50.00 - Corinne Jenkins Goldman Sachs Raises Buy $52.00 $42.00 Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Rhythm Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state ...Full story available on Benzinga.com
Benzinga • 1mo ago
Management Management statements
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
-- Proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 -- -- Proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 --
GlobeNewswire Inc. • 1mo ago
stocks Clinical Study
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
-- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce body weight and hyperphagia, no hyperpigmentation observed in preclinical studies --
GlobeNewswire Inc. • 1mo ago
News Clinical Study
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
-- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce body weight and hyperphagia, no hyperpigmentation observed in preclinical studies --
GlobeNewswire Inc. • 1mo ago
Stocks Major shareholder announcements
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on March 6, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 13,780 shares of its common stock to three new employees, consisting of inducement stock options to purchase an aggregate of 9,180 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 4,600 shares of its common stock.
GlobeNewswire Inc. • 2mo ago
Calendar Calendar of Events
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the Company will participate in two upcoming investor conferences.
GlobeNewswire Inc. • 2mo ago
Analyst Analyst Ratings
Analyst Expectations For Rhythm Pharmaceuticals's Future
Across the recent three months, 9 analysts have shared their insights on Rhythm Pharmaceuticals (NASDAQ:RYTM), expressing a variety of opinions spanning from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 7 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 3 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 2 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $49.89, with a high estimate of $55.00 and a low estimate of $42.00. This upward trend is apparent, with the current average reflecting a 26.53% increase from the previous average price target of $39.43. Investigating Analyst Ratings: An Elaborate Study A comprehensive examination of how financial experts perceive Rhythm Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Joseph Stringer Needham Maintains Buy $50.00 - Corinne Jenkins Goldman Sachs Raises Buy $52.00 $42.00 Joseph Stringer Needham Maintains Buy $50.00 - Corinne Jenkins Goldman Sachs Raises Buy $52.00 $42.00 Joseph Stringer Needham Raises Buy $50.00 $45.00 Jeffrey Hung Morgan Stanley Raises Overweight $55.00 $29.00 Derek Archila Wells Fargo Raises Overweight $53.00 $48.00 Corinne Jenkins Goldman Sachs Raises Buy $42.00 $38.00 Joseph Stringer Needham Raises Buy $45.00 $32.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Rhythm ...Full story available on Benzinga.com
Benzinga • 2mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT